Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akiva Diamond

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|April 12, 2024
From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapiesAkiva Diamond
Thrombosis Research|August 14, 2020
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and managementMouhamed Yazan Abou-Ismail, Akiva Diamond, Sargam Kapoor, et al.
JACC. Cardiooncology|May 5, 2023
Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL PatientsAkiva Diamond, Wyatt P Bensken, Long Vu, et al.
Hematological Oncology|June 1, 2022
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclinesAkiva Diamond, Sabarish Ayyappan, Shufen Cao, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2021
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse RatesMadison Keenan, Akiva Diamond, Kirsten Boughan, et al.
Blood Neoplasia|June 2, 2025
Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital systemJun Y Jiang, Chijioke Nze, Danielle Guffey, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2025
Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health SystemTrung Minh Nguyen, Jason Lu, Danielle Guffey, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|April 12, 2024
From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapiesAkiva Diamond
Thrombosis Research|August 14, 2020
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and managementMouhamed Yazan Abou-Ismail, Akiva Diamond, Sargam Kapoor, et al.
JACC. Cardiooncology|May 5, 2023
Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL PatientsAkiva Diamond, Wyatt P Bensken, Long Vu, et al.
Hematological Oncology|June 1, 2022
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclinesAkiva Diamond, Sabarish Ayyappan, Shufen Cao, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2021
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse RatesMadison Keenan, Akiva Diamond, Kirsten Boughan, et al.
Blood Neoplasia|June 2, 2025
Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital systemJun Y Jiang, Chijioke Nze, Danielle Guffey, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2025
Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health SystemTrung Minh Nguyen, Jason Lu, Danielle Guffey, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Pageof 1